UNIVERSIDAD DE BURGOS

Compounds capable of facilitating the transmembrane anion transport for the treatment of Cystic Fibrosis

Posted by UNIVERSIDAD DE BURGOSResponsive · Patents for licensing · Spain

Summary of the technology

The field of the invention is related to compounds containing a triazole-dipyrromethene core which facilitate the anion transport through lipid membranes. These molecules are capable of mimicking the function of transmembrane proteins and thus replacing their function at cellular level. These compounds are particular useful for the treatment of diseases related to malfunction of natural anion transport mechanisms such as Cystic Fibrosis.

UNIVERSIDAD DE BURGOS

New and innovative aspects

There are very limited studies in the literature concerning the possibility of using synthetic transport systems to replace the missing transmembrane anion transport activity characteristic of Cystic Fibrosis. Most of them referred to the use of peptides which degradability limited the potential scope of this approach.

The current invention provides a significant contribution related to the characterization, design and synthesis of small molecules with anion transport capacity, and their biological activity.

Main advantages of its use

The current standard therapies for Cystic Fibrosis are based mainly in palliative treatments of the illness symptoms. Recently it has been approved for use a drug that acts on the root of this problem, enhancing the transport of ions through natural channels, but only applicable to patients suffering from certain genetic mutations of the CFTR transmembrane protein.

These small molecules facilitate the transmembrane transport of anions independently of the genetic mutation, therefore they are therapy applicable to all Cystic Fibrosis patients, regardless of the type of mutation they harbor.

Specifications

Compounds bearing triazole-dipyrromethane moieties are capable of facilitating transport of anions such as chloride and of bicarbonate in phospholipid vesicles models and cells.

Applications

Use of the compound for preparing a medicament for the treatment and / or prophylaxis of conditions arising from abnormalities in the anion transport at the cellular level such as Cystic Fibrosis.

Intellectual property status

Protected by patent P201531749

Current development status

Samples ready for testing

Desired business relationship

Trade Agreement, License Agreement, Technical cooperation: further development, Technical Cooperation: testing of new applications; Technical Cooperation: adaptation to specific needs.

Related keywords

  • Biological Sciences
  • Genetic Engineering / Molecular Biology
  • Medical Health related
  • cystic fibrosis
  • transmembrane transport
  • anion
  • small molecules
  • treatment
  • rare disease

About UNIVERSIDAD DE BURGOS

Technology Transfer Office from Spain

The aim of the The Technology Transfer Office (TTO) of the Univesidad de Burgos is to promote Innovation technology through the reseach results transfer and the conexions between the University and the new needs and requirements of the society - we are the link between the University and the Industry. Contact person: José Manuel López (jmllopez@ubu.es)



Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.